drugset / Trial / NCT01688635
A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
RandomizedCrossoverDouble-blindBasic science
Summary
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®. The study will have 4 periods. In each period, a single injection will be administered before undergoing a euglycemic clamp that lasts for 24 hours. There will be at least a 7 day washout between each period. Side effects will be documented. Study participation is expected to last up to 14 weeks.
Timeline
- Start
- 2012-09
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2963016 | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
Indications
No indication recorded.